MeiraGTx Holdings PLC【MGTX】株式ニュース

Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&AFebruary 17, 2026 9:00 AM
InvestorsHub NewsWireFebruary 17th, 2026 -- InvestorsHub NewsWire -- via BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as Oncotelic Therapeutics Inc. (OTCQB:OTLC) (Profile), which holds multiple clinical-stage and late-stage programs across oncology and central nervous system ("CNS") indications, into focus as strategic assets aligned with current M&A priorities. The company just announced key advancements in its global intellectual property portfolio supporting OT-101, its proprietary TGF-ß antisense therapeutic platform. The advancements strengthen protection across neurology, oncology and central nervous system ("CNS") drug delivery designed to delivery drugs into the brain by getting through the blood brain barrier. This M&A trend bolsters Oncotelic Therapeutics' position in the oncology and CNS sectors as the OTLC joins other companies focused on the space, including Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR), MeiraGTx Holdings plc (NASDAQ:MGTX), Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) and Johnson & Johnson (NYSE:JNJ).

Central nervous system disorders such as brain cancer, Alzheimer's Disease, Parkinson's Disease and others represent one of the largest and most challenging therapeutic categories in modern medicine.
The convergence ance of CNS and oncology makes Oncotelic's update on expanding international IP coverage for OT-101 even more impactful.
Oncotelic Therapeutics' focus on delivery approaches relevant to CNS and oncology aligns with the industry's direction.
Oncotelic Therapeutics' development of OT-101 demonstrates its advanced R&D capabilities and innovative repositioning approach by exploring applications across oncology indications supported by mechanistic rationale and prior clinical research.
Oncotelic Therapeutics positions itself with a diversified portfolio spanning oncology-focused therapies, CNS indications and delivery technologies.

Click here to view the custom infographic of the Oncotelic Therapeutics editorial.

Big Pharma's Shift Toward Proven Assets

Biopharma dealmaking has increasingly centered on external innovation, licensing, and acquisitions of assets that demonstrate clinical validation. Strategic analyses from McKinsey & Company describe continued reliance on partnerships and acquisitions to replenish pipelines as internal R&D productivity challenges persist. Similarly, Deloitte's life sciences M&A outlook highlights ongoing selectivity and capital discipline, encouraging companies to prioritize assets with clearer development paths and measurable progress toward commercialization.

This strategic pivot reflects economic realities. Drug-development timelines remain long and costly, and investors have increasingly favored programs that demonstrate human safety or efficacy signals. Late-stage assets can reduce scientific uncertainty because clinical data provides clearer insight into safety profiles, dosing parameters, and potential regulatory pathways. As a result, companies nearing pivotal studies or late clinical phases may attract greater interest from acquirers seeking faster paths to market entry.

Oncology and CNS programs have emerged as particularly strategic targets within this framework. Oncology continues to dominate pharmaceutical pipelines due to large commercial markets and ongoing innovation, while CNS disorders represent some of the most significant unmet medical needs globally. Assets that bridge these areas may offer differentiated positioning, especially when they address complex biological pathways or delivery challenges that have historically limited therapeutic success.

Platforms supported by existing human data also carry valuation advantages. Programs that demonstrate clinical activity provide tangible milestones that investors can evaluate, reducing uncertainty compared with early discovery-stage platforms. This dynamic is contributing to growing attention toward companies holding clinical-stage portfolios rather than single preclinical assets.

Oncotelic Therapeutics fits this strategic profile through its clinical-stage pipeline focused on oncology and CNS-related targets. A clinical-stage biopharmaceutical developer, the company is pursuing therapies for cancer and other serious conditions. Oncotelic's programs, including those targeting TGF-ß signaling and delivery-focused approaches, align with the broader industry emphasis on validated mechanisms and diversified development strategies.

CNS, Oncology Markets Are Converging

Central nervous system disorders represent one of the largest and most challenging therapeutic categories in modern medicine. The World Health Organization reports that neurological conditions are now among the leading causes of disability and illness worldwide, affecting more than one in three people globally. The growing burden of neurodegenerative disease has intensified the need for innovative treatments capable of addressing complex biological mechanisms.

Alzheimer's disease illustrates the scale of this unmet need. The Alzheimer's Association estimates that millions of Americans currently live with the disease and that the economic burden continues to rise sharply, reflecting both healthcare costs and societal impact. Parkinson's disease shows similar trends, with prevalence expected to increase as populations age, reinforcing the long-term importance of CNS therapeutic innovation.

The intersection between oncology and CNS research is becoming increasingly relevant because many biological pathways operate across disease categories. Immune regulation, inflammation and signaling pathways involved in tumor progression can also influence neurological disease processes. These overlaps create opportunities for therapeutic platforms that can be developed across multiple indications, potentially expanding commercial reach while leveraging shared scientific insights.

From an investment perspective, cross-indication platforms may offer strategic advantages by enabling companies to pursue multiple markets simultaneously. Pharmaceutical companies evaluating acquisitions often look for mechanisms that extend beyond a single indication, as this can increase potential return on investment and support lifecycle management strategies.

Oncotelic Therapeutics' development strategy reflects this convergence by focusing on pathways such as TGF-ß modulation, which has been extensively studied in oncology and immune regulation contexts. Research documents the role of TGF-ß signaling in cancer biology and tumor microenvironment regulation. By targeting mechanisms relevant across multiple disease categories, the company aligns with the broader trend toward integrated therapeutic platforms.

New Milestones Expand Long-Term Potential

This convergence makes Oncotelic's update on expanding international IP coverage for OT-101, it's proprietary TGF-ß antisense therapeutic platform, even more impactful. The company, along with Sapu Bioscience, noted that the platform "[strengthens] protection across neurology, oncology, and central nervous system ("CNS") drug delivery."

OT-101 has multiple prior clinical trials conducted in various oncology indications including glioblastoma and pancreatic cancers. The compound was also investigated for additional applications in Acute Respiratory Distress Syndrome ("ARDS") and COVID-19-related inflammatory conditions. Building on its established clinical foundation in oncology, the Company is advancing OT-101 as a broader central nervous system ("CNS")-capable therapeutic platform, supported by targeted delivery technologies and expanded intellectual property coverage.

The update noted that in Australia, the company has received allowed patent claims explicitly covering OT-101 for the treatment of Parkinson's disease, while in China and Germany, utility model patents have been granted that provide device-level protection for continuous intracranial infusion technologies relevant to CNS therapeutics. "Collectively, these IP developments establish an integrated OT-101 CNS commercialization platform, combining therapeutic use claims in neurology with granted delivery-device protection," stated the company, which believes this expanded IP estate enhances OT-101's strategic value and supports future development, partnering, and commercialization efforts across oncology and neurological indications.

"OT-101 has a well-established clinical foundation, including prior clinical trials in multiple oncology indications, including glioblastoma, and these new IP milestones significantly expand its long-term potential," said Oncotelic CEO Dr. Vuong Trieu. "By securing Parkinson's disease claims in Australia and strengthening CNS delivery protection in China and Germany, we are building a globally defensible platform that supports both therapeutic use and delivery, while positioning the company for strategic partnerships and long-term shareholder value creation."

Drug Delivery Emerges as Strategic Differentiator

Drug delivery has become an increasingly important focus area within biotech innovation, particularly for CNS therapies. The blood–brain barrier presents a significant biological obstacle, preventing many drugs from reaching effective concentrations within brain tissue. Peer-reviewed research highlights that this barrier can limit therapeutic success even when a drug demonstrates strong activity in preclinical models.

Because of these challenges, delivery technologies capable of improving targeting or bioavailability are gaining strategic importance. Researchers increasingly view delivery systems as enabling technologies that can unlock previously inaccessible therapeutic pathways. Rather than viewing delivery as secondary to molecular discovery, investors and developers are recognizing it as a critical component of therapeutic success. Regulatory agencies also acknowledge the importance of delivery innovation. The U.S. Food and Drug Administration maintains specific frameworks for evaluating combination products that integrate drug and device components, underscoring the role administration methods play in clinical outcomes

From a strategic standpoint, companies developing delivery technologies alongside therapeutic mechanisms may offer differentiated value propositions. Improved delivery can enhance safety, reduce systemic toxicity, or increase efficacy by concentrating treatment within target tissues.

Oncotelic Therapeutics' focus on delivery approaches relevant to CNS and oncology aligns with this industry direction. By emphasizing methods that may enhance therapeutic targeting and overcome biological barriers, the company operates within a segment increasingly viewed as a critical bottleneck, and therefore a strategic value driver, in modern drug development.

Platform Repositioning Drives Capital Efficiency

Biotech strategy increasingly emphasizes capital efficiency, and one emerging approach involves repositioning clinically validated mechanisms into additional therapeutic indications. Rather than starting from entirely new discovery programs, companies are expanding existing platforms into adjacent markets where scientific rationale already exists.

This strategy can reduce risk because safety data and mechanistic understanding from earlier studies may inform future development pathways. Repositioning also allows companies to maximize the value of prior investments by generating multiple clinical opportunities from a single biological target or technology platform.

The TGF-ß pathway provides a strong example of this approach. Extensive scientific literature describes its role in tumor growth, immune modulation and inflammation, creating opportunities for therapies targeting this pathway across multiple diseases. Advances in understanding tumor microenvironment biology have renewed interest in therapeutic strategies that modulate TGF-ß signaling.

Oncotelic Therapeutics' development of OT-101, which targets TGF-ß2 mRNA, illustrates a repositioning approach by exploring applications across oncology indications supported by mechanistic rationale and prior clinical research. Studies investigating OT-101 in combination with standard therapies reflect ongoing efforts to expand its potential clinical applications.

Platform repositioning may also enhance strategic flexibility for potential partners or acquirers. Companies capable of adapting mechanisms to multiple disease contexts can respond to evolving market conditions or regulatory landscapes, increasing long-term development optionality.

Diversified Pipelines Reduce Binary Investment Risk

Historically, biotech investment has often centered on single-asset companies, where success or failure depended heavily on one clinical outcome. However, diversified pipelines are increasingly viewed as advantageous because they distribute risk across multiple programs and timelines.

A multiasset strategy can provide resilience during clinical development, as setbacks in one program may be offset by progress in others. This diversification can also create multiple value inflection points, attracting investors seeking reduced exposure to binary outcomes while maintaining exposure to breakthrough innovation.

From an M&A perspective, diversified pipelines may increase strategic appeal because acquirers gain optionality. A single acquisition can provide access to multiple therapeutic candidates, allowing pharmaceutical companies to prioritize programs based on evolving market needs or scientific progress.

As the biotech industry continues to emphasize late-stage validation, platform versatility and capital efficiency, companies combining diversified clinical programs with differentiated scientific approaches may increasingly attract attention from strategic partners and acquirers seeking to balance innovation with reduced development risk.

Oncotelic Therapeutics positions itself within this diversified model through a portfolio spanning oncology-focused therapies, CNS indications and delivery technologies. The company's pipeline includes multiple assets at varying development stages, which may reduce reliance on a single program outcome while supporting broader strategic positioning.

Pharma Deals Signal Strategic Shift

The pharmaceutical space continues to evolve through strategic partnerships, targeted acquisitions and collaborative innovation designed to accelerate drug development and expand therapeutic pipelines. Recent announcements across the sector highlight a focus on neurological disorders, RNA-based therapies and AI-driven research approaches, reflecting how leading operators are positioning themselves to capture future growth opportunities while addressing significant unmet medical needs.

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) reported a global licensing and collaboration agreement with Novartis. The agreement is for ARO-SNCA, Arrowhead's preclinical stage siRNA therapy against alpha-synuclein for the treatment of synucleinopathies, such as Parkinson's disease, and for other additional collaboration targets that will utilize Arrowhead's proprietary Targeted RNAi Molecule (TRiM[TM]) platform. Upon closing, Arrowhead will receive $200 million as an upfront payment and is eligible to receive up to $2 billion in potential milestone payments plus royalties on commercial sales.

MeiraGTx Holdings plc (NASDAQ:MGTX) announced the formation of a joint venture with Hologen Limited. According to the announcement, MeiraGTx will receive $200 million in upfront cash at closing of the JV, called Hologen Neuro AI Ltd. In addition to the $200 million upfront payment to MeiraGTx, Hologen Neuro AI will be funded with committed capital of up to $230 million from Hologen to fully finance the development of AAV-GAD for the treatment of Parkinson's disease through to commercialization, as well as funding earlier stage clinical programs in the CNS, including AAV-BDNF for genetic obesity. Hologen will contribute its proprietary multi-modal generative foundation models ("LMMs") to the joint venture.

Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) completed the acquisition of Sage Therapeutics for approximately $561 million upfront, with contingent value rights ("CVR") that could bring total consideration up to about $795 million. The transaction will provide Supernus with an innovative marketed product: ZURZUVAE(R) (zuranolone) capsules CIV, the first and only U.S. Food and Drug Administration ("FDA")-approved oral medicine indicated for the treatment of adults with postpartum depression.

Johnson & Johnson (NYSE:JNJ) has entered into a definitive agreement to acquire all outstanding shares of Intra-Cellular Therapies in a $14.6 billion transaction. Intra-Cellular Therapies is a biopharmaceutical company focused on the development and commercialization of therapeutics for CNS disorders. With this agreement, Johnson & Johnson adds Intra-Cellular Therapies' CAPLYTA(R)(lumateperone), a once-daily oral therapy approved to treat adults with schizophrenia, as well as depressive episodes associated with bipolar I or II disorder (bipolar depression), as a monotherapy and adjunctive therapy with lithium or valproate.

These developments underscore a broader transformation underway in pharma, where collaboration, platform technologies and portfolio expansion are becoming central to long-term strategy. As companies pursue high-value deals and innovative partnerships, investors and industry observers alike are watching closely to see how these initiatives translate into clinical advancement, commercial success and sustained competitive advantage.

For further information about Oncotelic Therapeutics Inc., visit the Oncotelic Therapeutics profile.

About BioMedWire

BioMedWire ("BMW") is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, "Biotech" to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

DISCLAIMER: BioMedWire (BMW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by BMW are solely those of BMW. Readers of this Article and content agree that they cannot and will not seek to hold liable BMW for any investment decisions by their readers or subscribers. BMW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, BMW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment.

BMW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BMW undertakes no obligation to update such statements.

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire

Austin, Texas

www.BioMedWire.com

512.354.7000 Office

Editor@BioMedWire.com

BioMedWire is powered by IBN
Original: Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A

Over $5 5.70 + 22% MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s Disease

Source: GlobeNewswire Inc.

MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced top-line data from its clinical bridging study of AAV-GAD for the treatment of Parkinson’s disease, MGT-GAD-025.
MGT-GAD-025 is a 6-month, three-arm, randomized, double-blind, sham-controlled study using AAV-GAD drug product manufactured by MeiraGTx at its wholly-owned facilities with its commercial platform process. Participants had idiopathic Parkinson's disease, a history of levodopa responsiveness for at least 12 months, and a UPDRS Part 3 score of ≥25 points in the "off" state. Fourteen subjects were randomized to one of three groups (high dose n=5, low dose n=5, and sham n=4).

Subjects received either AAV-GAD infused bilaterally into the subthalamic nucleus or a sham procedure in a blinded fashion. The total dose per treated participant was 7.0×1010 vg (low dose group) or 21×1010 vg (high dose group). The primary objective of the study was to evaluate the safety and tolerability of AAV-GAD, with exploratory efficacy endpoints including the mean change from baseline to Week 26 in MDS-UPDRS Part 3 (motor examination) scores in the “off” state and the Parkinson’s Disease Questionnaire (PDQ-39) score, a key patient-reported quality of life measure in Parkinson’s disease. Subjects who completed this trial may enroll in a long-term follow-up study (NCT05894343), where they will be monitored for a total of five years post-treatment.

Top-line data summary:

AAV-GAD was safe and well tolerated, with no serious adverse events (SAEs) related to AAV-GAD treatment.
At Week 26, a statistically significant 18-point average improvement from baseline in UPDRS Part 3 “off” medication score was demonstrated in the high dose group (p=0.03), with no significant change in the sham or low dose groups.
Significant improvements from baseline in the disease-specific, patient-reported quality of life PDQ-39 score were demonstrated in both the high and low dose groups with no significant change in the sham group at Week 26:
In the high dose AAV-GAD group, the PDQ-39 score improved by 8 points from baseline (p=0.02), the low dose group improved by 6 points from baseline (p=0.04), while the 0.2 point worsening in the sham surgery group was not statistically significant.
A dose response in PDQ-39 score was observed, with 100% of participants in the high dose group, 60% of participants in the low dose group, and 25% of participants in the sham surgery group reporting an improvement.
For the PDQ-39 score, there was a trend to significance between the high dose and sham surgery groups at 6 months (n=4 evaluable per group).
Dr. Ali Rezai, M.D., executive chair of the Rockefeller Neuroscience Institute at West Virginia University (WVU), past president of the Congress of Neurological Surgeons, and principal investigator of the AAV-GAD study, stated, “These safety and outcome results are excellent. The extent of motor score improvements in patients who received the high dose treatment combined with significant quality of life improvement measures are very encouraging for both patients and physicians.”

“We are excited about these impressive clinical data in Parkinson’s disease,” said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx. “With material made using our proprietary production process at commercial scale, we have demonstrated that AAV-GAD is safe at all doses studied, including a higher dose than previously tested. We have now treated a total of 58 patients in this development program in 3 independent multicenter clinical studies and have seen no SAEs related to AAV-GAD treatment.”

Dr. Forbes continued, “With the completion of this randomized, double-blinded bridging study, we have also demonstrated with even very small numbers of subjects that AAV-GAD treatment results in significant and clinically meaningful changes in key efficacy endpoints in Parkinson’s disease. For the UPDRS Part 3 in the “off” state, a change of 5 to 10 points is considered clinically meaningful. The 18-point change observed in the high dose arm in this study underscores the very substantial impact of AAV-GAD treatment in these Parkinson’s patients. Similarly, for the PDQ-39, where a 2 to 4-point change is considered clinically meaningful, the 8-point and 6-point changes observed in the high and low dose groups, respectively, again indicate a substantial and clinically meaningful impact of AAV-GAD treatment.”

“These data demonstrate the impact of using highly targeted local delivery of gene-based therapy to correct the aberrant circuitry that results from the depletion of dopamine in the brain of idiopathic Parkinson’s patients as the disease progresses. AAV-GAD treatment is designed to normalize circuit function in all forms of Parkinson’s disease with its potential benefit not limited to any single type of Parkinson’s. The significant, substantial, and clinically meaningful changes observed in this small, sham-controlled study provide us with a clear path forward in our clinical development strategy and underpin our discussions with regulators in the US, Europe, and Japan with the goal of initiating a Phase 3 study to support approval of this disease-modifying treatment globally.”

About AAV-GAD

Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s, with nearly one million people in the U.S. currently living with Parkinson’s disease and approximately 90,000 new patients diagnosed annually in the U.S. There are more than 10 million people worldwide currently living with PD. Most individuals with PD initially respond to dopamine replacement therapy, yet for a large percentage of patients, over time, this type of treatment is no longer sufficiently helpful while adverse effects of medication can also occur, leading to a considerable reduction in quality of life and the ability to function effectively. The cause of Parkinson’s disease is unknown for a majority of patients, while a much smaller percentage have a known genetic cause, but in all cases, there is dysfunction of the key circuits that control movement. AAV-GAD is an investigational gene therapy designed to reprogram these dysfunctional brain circuits through the local production of GABA, a chemical neurotransmitter that can help restore more normal activity to these critical cells in any form of PD. AAV-GAD is delivered via a one-time infusion through a minimally invasive procedure, using a MeiraGTx proprietary device that allows infusion of the equivalent of one drop of gene therapy solution into the subthalamic nucleus, a key regulator of the circuits responsible for normal movement.

About MeiraGTx

MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs supported by end-to-end manufacturing capabilities. MeiraGTx has internal plasmid production for GMP, two GMP viral vector production facilities as well as an in-house Quality Control hub for stability and release, all fit for IND through commercial supply. In addition, MeiraGTx has developed a proprietary manufacturing platform with leading yield and quality aspects and commercial readiness, MeiraGTx has core capabilities in viral vector design and optimization and a transformative riboswitch gene regulation platform technology that allows for the precise, dose-responsive control of gene expression by oral small molecules. MeiraGTx is focusing the riboswitch platform on the delivery of metabolic peptides, including GLP-1, GIP, Glucagon, and PYY, using oral small molecules, as well as cell therapy for oncology and autoimmune diseases. MeiraGTx has developed the technology to apply genetic medicine to more common diseases, increasing efficacy, addressing novel targets, and expanding access in some of the largest disease areas where the unmet need remains high.